Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Sep 13, 2018 in Leukemia | 0 comments

In a nutshell

This study looked at the current evidence for the effect of changing genes in T-cells (a type of immune cell) to target cancer cells in acute lymphoblastic leukemia (ALL). The study found that these T-cells were safe and effective in the treatment of ALL.

Some background

Acute Lymphoblastic Leukemia is a type of bone marrow cancer which leads to a weakened immune system. T-cells are an important part of the immune response. It may be possible to modify these T-cells to attack cancer cells in patients with ALL. It is important to research if this is a safe and effective treatment method.

Methods & findings

Evidence reviewed showed that studies which have looked at T-cell therapy have had varied methods, analysis, and grading of safety and effectiveness.

Treatment with a single-dose of T-cell therapy resulted in complete remission (no signs of cancer after treatment) in 70-90% of cases. Side effects of this treatment include damage to nerves, fever, muscle pain and organ failure.

Although the positive effects of T-cell therapy are long-lasting, some patients experience relapse (return of cancer). Some studies showed that these patients may benefit from a stem cell transplant after achieving remission from T-cell therapy.

The bottom line

The study concluded that safety and effectiveness of T-cell therapy in patients with ALL was positive and similar across current evidence.

The fine print

The study notes that abnormal genes in an individual have a large impact on the safety and effectiveness of T-cell therapy.

What’s next?

Talk to your doctor about the possibility of T-cell therapy for the treatment of ALL.

Published By :

Current hematologic malignancy reports

Date :

Aug 17, 2018

Original Title :

CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.

click here to get personalized updates